Want to see WHWK full AI Analyst Report?
WHWK Stock Chart & Stats
$3.71
>-$0.01(-0.27%)
At close: 4:00 PM EDT
$3.71
>-$0.01(-0.27%)
Day’s Range― - ―
52-Week Range$1.68 - $5.50
Previous CloseN/A
Volume49.01K
Average Volume (3M)3.35M
Market Cap
$275.35M
Enterprise Value$189.64
Total Cash (Recent Filing)$189.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 11, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding57,009,010
10 Day Avg. Volume9,835,549
30 Day Avg. Volume3,352,856
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.25Price Target Upside122.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.23
Revenue Forecast (FY)-$1.50M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal leverage and a larger equity base provide a capital buffer that can support operations and reduce immediate solvency pressure, giving management more flexibility while clinical programs advance.
Pipeline ExpansionBroadening the CPT113 platform can increase pipeline depth and future partnering opportunities. Retained global rights and target selection preserve strategic control as multiple programs move toward IND filings.
External Platform ValidationExternal clinical activity and favorable safety observations support the potential utility of CPT113 beyond Whitehawk's own programs. This may improve development confidence and strengthen the platform's partnering appeal.
Bears Say
No Current RevenueThe absence of trailing revenue means Whitehawk currently lacks commercial operating support for research and corporate costs. Future funding and value creation therefore remain dependent on successful clinical and regulatory progress.
Persistent Operating LossesLarge recurring losses indicate that costs remain structurally high relative to revenue. Unless clinical programs produce approvals, partnerships, or commercialization income, profitability is unlikely to provide a durable funding source.
Heavy Cash BurnSustained negative cash generation limits financial self-sufficiency and can require repeated financings to maintain development activity. Over time, this creates dilution risk and increases dependence on capital-market access.
Whitehawk Therapeutics News
WHWK FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was $1.68 and its highest was $5.50 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is $275.35M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.296 by $0.096.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 57,009,010 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.296. Following the earnings report the stock price went up 15.479%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in WHWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
WHWK Stock 12 Month Forecast
Average Price Target
$8.25
▲(122.37% Upside)
Technical Analysis
Ownership Overview
26.37% Insiders
3.44% Mutual Funds
61.92% Other Institutional Investors
3.18% Public Companies and
Individual Investors